Cardinal Health reported robust first-quarter fiscal year 2025 results, with non-GAAP diluted earnings per share (EPS) increasing 9% year-over-year to $1.88, surpassing consensus estimates. Consolidated revenue for the quarter was $52.3 billion, a 4% decrease from the prior year, but increased 15% when excluding the impact of a large customer contract expiration.
The Pharmaceutical and Specialty Solutions segment was a key driver of performance, with segment profit increasing 16% to $530 million. This growth was fueled by higher contributions from brand and specialty products, including early seasonal COVID-19 vaccine distribution, and strong generics program performance. Excluding the customer contract expiration, segment revenue increased 16%.
Based on this strong start, Cardinal Health raised its fiscal year 2025 non-GAAP diluted EPS guidance to a range of $7.75 to $7.90, up from the previous range of $7.55 to $7.70. The company also updated its Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, reflecting increased confidence in its largest business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.